Clinical Trials Logo
  1. Home
  2. Disease, Hodgkin
  3. NCT00848926

A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma

Disease, Hodgkin Clinical Trial

Official title:
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)

Clinical Trial Summary

This is a single-arm, open-label, multicenter, pivotal clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory Hodgkin lymphoma.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00848926
Study type Interventional
Source Seattle Genetics, Inc.
Contact
Status Completed
Phase Phase 2
Start date February 2009
Completion date May 2015
View Details
See also
  Status Clinical Trial Phase
Completed NCT00430846 - Phase I Open-Label Dose Finding Study of SGN-35 for CD30 Positive Hematologic Malignancies Phase 1
Terminated NCT00649584 - A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies Phase 1
Completed NCT00947856 - A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study Phase 2
Completed NCT01060904 - A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma Phase 1
Completed NCT01026233 - Cardiac Safety Study of Brentuximab Vedotin (SGN-35) Phase 1
Completed NCT01026415 - Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35) Phase 1
Completed NCT01100502 - A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial) Phase 3
No longer available NCT01196208 - A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001